All In Biotech

Drug Trial Radar · NCT06751485

JSKN003 in Platinum-Resistant, Relapsed Epithelial Ovarian Cancer

A Randomized, Open-Label, Parallel-Controlled, Multi-center Phase Ⅲ Study of JSKN003 Versus Investigator-Choice Chemotherapy for Platinum-Resistant, Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Last checked: Nov 20, 2026Latest source record: Dec 31, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 430 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

430

Planned (sponsor's estimate)

Start

Jan 15, 2025

Primary completion

Dec 30, 2026

Study completion Dec 30, 2027

Sponsor

Sponsor type
Industry
First posted
Dec 30, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a randomized, open-label, controlled, phase III study to evaluate the efficacy and safety of JSKN003 versus investigator's choice of chemotherapy in patients with platinum-resistant, relapsed epithelial Ovarian, primary peritoneal, or fallopian tube cancer.

Conditions

  • Ovarian Cancer
  • Primary Peritoneal
  • Fallopian Tube Cancers

Interventions

  • JSKN003Drug

    Experimental drug

  • DoxorubicinDrug

    Active Comparator

  • PaclitaxelDrug

    Active Comparator

  • TopotecanDrug

    Active Comparator

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free Survival (PFS) assessed by Blinded Independent Review Committee (BIRC) as per RECIST 1.1Time frame: Up to approximately 22 months

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.